Literature DB >> 11895803

Increased soluble and platelet-associated CD40 ligand in essential thrombocythemia and reactive thrombocytosis.

Jean-François Viallard1, Anne Solanilla, Bruno Gauthier, Cécile Contin, Julie Déchanet, Christophe Grosset, Jean-François Moreau, Vincent Praloran, Paquita Nurden, Jean-Luc Pellegrin, Alan T Nurden, Jean Ripoche.   

Abstract

CD40 ligand (CD40L) is expressed on activated CD4(+) T lymphocytes and at the activated platelet surface. A circulating soluble form of CD40L (sCD40L) is generated by the way of a proteolytic cleavage. We measured sCD40L in the plasma of either healthy subjects; patients with inflammatory disorders and low, normal, or high platelet count (reactive thrombocytosis); or patients with essential thrombocythemia (ET). A tight correlation was found between the platelet count and plasma sCD40L. ET patients had the highest levels of sCD40L. Platelet-associated CD40L was increased in ET and reactive thrombocytosis, conditions associated with increased platelet regeneration. Platelet-associated CD40L was released upon platelet activation. In conclusion, platelets appear as a reservoir of CD40L that may be a major contributor to circulating sCD40L. Platelet-associated CD40L may be a potential marker of platelet regeneration.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11895803     DOI: 10.1182/blood.v99.7.2612

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  24 in total

Review 1.  New molecular targets for treatment of lymphoma.

Authors:  Barbara Pro; Anas Younes
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

2.  Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura.

Authors:  X Feng; P Scheinberg; L Samsel; O Rios; J Chen; J P McCoy; W Ghanima; J B Bussel; N S Young
Journal:  J Thromb Haemost       Date:  2012-08       Impact factor: 5.824

3.  Developmental changes in soluble CD40 ligand.

Authors:  Jill M Cholette; Neil Blumberg; Richard P Phipps; Michael P McDermott; Kelly F Gettings; Norma B Lerner
Journal:  J Pediatr       Date:  2007-10-24       Impact factor: 4.406

4.  Lysyl oxidase is associated with increased thrombosis and platelet reactivity.

Authors:  Shinobu Matsuura; Rongjuan Mi; Milka Koupenova; Alexia Eliades; Shenia Patterson; Paul Toselli; Jonathan Thon; Joseph E Italiano; Philip C Trackman; Nikolaos Papadantonakis; Katya Ravid
Journal:  Blood       Date:  2016-01-11       Impact factor: 22.113

5.  Platelet expression of PKCepsilon oncoprotein in myelofibrosis is associated with disease severity and thrombotic risk.

Authors:  Elena Masselli; Cecilia Carubbi; Giulia Pozzi; Silvia Martini; Franco Aversa; Daniela Galli; Giuliana Gobbi; Prisco Mirandola; Marco Vitale
Journal:  Ann Transl Med       Date:  2017-07

6.  Soluble CD40-ligand (sCD40L, sCD154) plays an immunosuppressive role via regulatory T cell expansion in HIV infection.

Authors:  M-A Jenabian; M Patel; I Kema; K Vyboh; C Kanagaratham; D Radzioch; P Thébault; R Lapointe; N Gilmore; P Ancuta; C Tremblay; J-P Routy
Journal:  Clin Exp Immunol       Date:  2014-10       Impact factor: 4.330

7.  Acute splenic infarction presenting as an unusual manifestation of essential thrombocythaemia with normal platelet count.

Authors:  Katsuyuki Yoshida; Ibuki Kurihara; Takahiko Fukuchi; Hitoshi Sugawara
Journal:  BMJ Case Rep       Date:  2019-07-03

Review 8.  Platelets and IgE: Shaping the Innate Immune Response in Systemic Lupus Erythematosus.

Authors:  Benoit Brilland; Marc Scherlinger; Liliane Khoryati; Julien Goret; Pierre Duffau; Estibaliz Lazaro; Manon Charrier; Vivien Guillotin; Christophe Richez; Patrick Blanco
Journal:  Clin Rev Allergy Immunol       Date:  2020-04       Impact factor: 8.667

9.  Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients.

Authors:  S Danese; J A Katz; S Saibeni; A Papa; A Gasbarrini; M Vecchi; C Fiocchi
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

10.  Effect of Danhong Injection Combined with Naoxintong Tablets on Prognosis and Inflammatory Factor Expression in Acute Coronary Syndrome Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Yun Lv; Yaping Pan; Yan Gao; Jingqian Lu; Yi Li; Jie Bai; Jing Zhai
Journal:  Acta Cardiol Sin       Date:  2015-07       Impact factor: 2.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.